ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial

This study has been completed.
Information provided by:
Daiichi Sankyo Inc.
ClinicalTrials.gov Identifier:
First received: August 31, 2005
Last updated: May 9, 2011
Last verified: May 2011
The purpose of the study is to evaluate the effectiveness and safety of olmesartan versus placebo on the progression of diabetic renal disease.

Condition Intervention Phase
Diabetic Nephropathy
Type 2 Diabetes Mellitus
Drug: olmesartan medoxomil
Drug: Placebo Tablets
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: CS-866DM Phase 3 Clinical Study: A Double-Blind Controlled Trial in Patients With Diabetic Nephropathy and Overt Proteinuria Secondary to Type 2 Diabetes Mellitus

Resource links provided by NLM:

Further study details as provided by Daiichi Sankyo Inc.:

Primary Outcome Measures:
  • Renal Composite Outcomes [ Time Frame: Randomization to 5 years ] [ Designated as safety issue: No ]
    first occurrence of any of the following events: Doubling of serum creatinine level; Death; End stage renal disease

Secondary Outcome Measures:
  • Number of Participants Experiencing Cardiovascular Composite Outcomes [ Time Frame: Within 5 years ] [ Designated as safety issue: No ]
    Number of participants experiencing the first occurence of any of the following: Cardiovascular death; non-fatal stroke; non-fatal myocardial infarction; hospitalization for unstable angina; lower extremity amputation; coronary/carotid/peripheral revascularization.

  • The Change in Proteinuria [ Time Frame: Randomization to 5 years ] [ Designated as safety issue: No ]
    The median percentage change from baseline value in urinary protein:creatinine ratio

  • Reciprocal (1/Serum Creatinine) of Serum Creatinine [ Time Frame: Randomization to 5 years ] [ Designated as safety issue: No ]
    The amount of serum creatinine was determined by blood tests periodically during the study. The amount of creatinine is an indication of kidney function. The reciprocal of serum creatinine is used in an equation to determine the change in kidney function from baseline. The reciprocal of the serum creatinine was monitored to detect kidney function changes over duration of the study.

Enrollment: 577
Study Start Date: April 2003
Study Completion Date: January 2009
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Olmesartan medoxomil tablets 10mg to 40 mg
Drug: olmesartan medoxomil
Tablets 10, 20, or 40 mg
Placebo Comparator: 2
Matching placebo tablets
Drug: Placebo Tablets
Matching placebo tablets


Ages Eligible for Study:   30 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • clinical diagnosis of diabetic nephropathy in patients with type 2 diabetes
  • albumin-to-creatinine ratio >= 300 mg/g creatinine in first morning urinalysis
  • serum creatinine between 1.0 and 2.5 mg/dL in women and between 1.2 and 2.5 mg/dL in men

Exclusion Criteria:

  • type 1 diabetes
  • non-diabetic nephropathy
  • history of myocardial infarction
  • history of cardiac bypass grafting within 3 months
  • history of percutaneous coronary intervention (PCI) within 6 months
  • history of carotid artery or peripheral artery revascularization within 6 months
  • stroke or transient ischemic attack (TIA) within 1 year
  • unstable angina pectoris
  • heart failure of NYHA functional classes III or IV
  • rapid progression of kidney disease within 3 months
  • severe orthostatic hypotension
  • serum potassium level =<3.5 mEq(mmol)/L or =>5.5 mEq(mmol)L
  • history of rapid elevation of the serum creatinine level after starting treatment with AII receptor antagonists or ACE inhibitors
  • poor glycemic control: HbA1c level =>11%
  • history of myocardial infarction (MI) or coronary artery bypass grafting (CABG) within 3 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00141453

Hong Kong, China
Tokyo, Japan
Sponsors and Collaborators
Daiichi Sankyo Co., Ltd.
Study Director: Study Manager R&D Division, Daiichi Sankyo Co., Ltd.
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Shuji Tsukiyama, Daiichi Sankyo Co., Ltd. Tokyo, Japan
ClinicalTrials.gov Identifier: NCT00141453     History of Changes
Other Study ID Numbers: ORIENT 
Study First Received: August 31, 2005
Results First Received: August 31, 2009
Last Updated: May 9, 2011
Health Authority: Japan: Ministry of Health, Labor and Welfare
Hong Kong: Department of Health

Keywords provided by Daiichi Sankyo Inc.:
angiotensin II type I receptor blockers
diabetic nephropathy
end-stage renal disease
renal failure
type 2 diabetes
olmesartan medoxomil

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetic Nephropathies
Kidney Diseases
Kidney Failure, Chronic
Diabetes Complications
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Renal Insufficiency
Renal Insufficiency, Chronic
Signs and Symptoms
Urination Disorders
Urologic Diseases
Urological Manifestations
Olmesartan Medoxomil
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Antihypertensive Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on May 25, 2016